To D/C or Not to D/C: Managing Hyperkalemia in the HF Patient on an ACE/ARB and/or MRA Optimizing Patient Benefits & Risks

To D/C or Not to D/C

Question Title

* 1. The most common adverse events seen in clinical trials for the novel and emerging potassium binders, patiromer and sodium zirconium cyclosilicate (ZS-9) were gastrointestinal events including diarrhea and constipation.

True

False

Question Title

* 2. Which of the following medications is composed of a non-absorbed potassium-binding polymer and a calcium-sorbitol counterion?

Sodium Polystyrene Sulfonate

Patiromer

Sodium Zirconium Cyclosilicate (ZS9)

Insulin/ Calcium / Bicarbonate

Question Title

* 3. Sodium zirconium cyclosilicate (ZS-9) is an investigational potassium binder that removes potassium by exchanging sodium for potassium. Phase III data shows that patients with hyperkalemia who received ZS-9 at a dose of 1.25 g, 2.5 g, 5 g, or 10 g or placebo three times daily for 48 hours, had a significant reduction in potassium levels at 48 hours, with _________________________________.

Normokalemia maintained during 5 days of maintenance therapy

Normokalemia maintained during 12 days of maintenance therapy

Normokalemia maintained for 10 days after discontinuation of therapy

Normokalemia maintained for 14 days after discontinuation of therapy

Question Title

* 4. Chronic heart failure patients are at increased risk for developing hyperkalemia, particularly when there is coexisting _________________.

Renal insufficiency or renal failure

Atrial Fibrillation

A left ventricular ejections fraction of less than 35%

Hyponatremia of less than 130 mmol/L

Question Title

* 5. Please provide your first and last name.
Pre-test questions will not be scored, your name is required solely to confirm completion.

First Name & Last Name